Specialty Pharmaceutical Management Consulting Firm Viscadia Hires Brandon Kocher

Specialty Pharmaceutical Management Consulting Firm Viscadia Hires Brandon Kocher

Washington D.C. – June 17, 2014 – Specialty pharmaceutical management consulting firm Viscadia Inc. is pleased to announce the addition of Brandon Kocher Ph.D. to their team as an associate consultant. While completing his Ph.D. and actively consulting for two non-profit organizations, Brandon accumulated diverse scientific expertise within oncology, inflammation, antibiotics and vaccine development, ocular pathologies, and medical devices. Brandon has advised a spectrum of businesses including venture groups, angel investors, accelerators/incubators, and various life-science companies and entrepreneurs.

"We are excited with the scientific expertise and life-science consulting and investment due diligence experience that Brandon brings to Viscadia and its clients," said Viscadia President and CEO, Satish Kauta.

Brandon acquired his Ph.D. from Washington University School of Medicine in St. Louis where he focused on researching breast cancer, novel anti-cancer therapeutics and advancing pre-clinical cancer models. Brandon earned a B.S. in biology with a focus in genetics and molecular biology from James Madison University.

Viscadia Inc. is an analytically driven management consulting firm that partners with companies in specialty pharmaceutical markets. Viscadia identifies and evaluates development, acquisition, licensing and life-cycle management opportunities. Additionally, Viscadia analyzes and optimizes the execution of specialty pharmaceutical commercial strategies. Viscadia is headquartered in Washington, D.C., with regional offices in San Diego, CA, and St. Louis, MO. For more information about Viscadia, email [email protected], call 202-540-9900 or visit www.viscadia.com.

Contact: Amy Zimmerman
A.Z. Communications
619-501-1875
[email protected] 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.